Journal of Clinical Oncology
Articles in this Issue
Overall survival from the phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in first-line metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects (BRCAAway).
16 Background: The BRCAAway trial evaluated the efficacy of abiraterone (Abi) versus olaparib (Ola) versus their combinati...
The clinical impact of germline variants in DNA repair genes in patients who underwent curative surgery for localized prostate cancer.
321 Background: Family history represents a significant risk factor for prostate cancer (PCa), emphasizing its genetic bas...
Using large language models for grading CTCAE toxicity after radiation therapy for prostate cancer.
357 Background: Prostate cancer (PCa) is the most incident cancer in adult males in the United States, and the second high...
EMPOWER01: A phase II study of zanidatamab combined with bacillus Calmette-Guerin (BCG) in HER2-positive high-risk non-muscle-invasive bladder cancer (HR NMIBC).
TPS899 Background: Zanidatamab was a humanised, bispecific monoclonal antibody directed against two non-overlapping domain...
Ultra-hypofractionated radiotherapy and concomitant oral relugolix for treatment of intermediate risk prostate cancer (ULTRA-HERO).
TPS411 Background: Radiotherapy (RT) and concomitant short course androgen deprivation therapy (ADT) is one of the standar...
Autoantibody (AAb) profiling in metastatic cisplatin-ineligible metastatic urothelial carcinoma (mUC) treated with ipilimumab (IPI), nivolumab (NIVO), and sacituzumab govitecan (SG).
863 Background: We previously reported that the combination of IPI-NIVO plus SG shows high efficacy with 83.3% objective r...
A phase II trial of intravesical gemcitabine/docetaxel plus systemic pembrolizumab in high-risk non–muscle invasive bladder cancer unresponsive to BCG.
TPS888 Background: High-risk non–muscle invasive bladder cancer (NMIBC) unresponsive/exposed to Bacillus Calmette-Guérin (...
Artificial intelligence (AI) as a practical decision support tool for oncologists: Genitourinary (GU) cancer cases.
565 Background: Multidisciplinary reviews (MDR) can significantly impact the management of oncologic patients, yet these a...
Use of circulating tumor DNA (ctDNA) in the detection of residual disease and recurrence for patients with testicular cancer.
620 Background: ctDNA has been increasingly investigated as a biomarker of interest for patients with testicular cancer, a...
Bladder full or empty for pelvic radiation therapy (BEFORE): A multi-center randomized controlled trial.
TPS408 Background: Pelvic radiation therapy plays a key role in the treatment of most genitourinary (GU), gynecologic (Gyn...
Imaging meets genomics in treatment-naïve prostate cancer: SUVmax on prostate-specific membrane antigen (PSMA) PET as a biomarker of genomic classifier risk.
267 Background: Genomic Classifiers (GC) are increasingly used at the initial staging of prostate cancer to refine prognos...
Genomic alterations and pathologic responses to neoadjuvant androgen receptor pathway inhibitor (ARPI) doublets vs docetaxel triplets in the Genomic Umbrella Neoadjuvant study (GUNS).
309 Background: GUNS (NCT04812366) is a multi-centre adaptive phase II trial evaluating 24 weeks of biomarker-selected, ne...
Analysis of CA9 and PSMA expression in clear cell renal cell carcinoma (ccRCC) and the effect of prior therapies.
547 Background: In ccRCC, carbonic anhydrase 9 (CA9) and prostate-specific membrane antigen (PSMA) have emerged as potenti...
Analysis of quality-adjusted time without symptoms or toxicity (Q-TWiST) in patients with metastatic hormone-sensitive prostate cancer: From the ARASENS trial.
133 Background: Triplet combination of darolutamide (DARO; an androgen receptor inhibitor) with androgen deprivation thera...
Healthcare resource utilization (HCRU) and costs among US patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) treated with first-line (1L) treatment regimens: Results from the ELEVATE UC-I study.
871 Background: While real-world safety of 1L tx regimens for la/mUC has been previously described, data characterizing HC...
Effect of HER2 IHC on enfortumab vedotin (EV) or EV+pembrolizumab (EVP) benefit in metastatic urothelial carcinoma.
780 Background: Nectin-4 is the primary target of enfortumab vedotin (EV), an antibody-drug conjugate approved for metasta...
Effect of remote exercise on fatigue and quality of life (QOL) across genitourinary (GU) cancer types.
487 Background: Patients with GU cancers experience declines in physical function and QOL during treatment. Exercise may i...
Prostate cancer screening in a geriatric population.
317 Background: PSA screening often results in diagnosis of clinically nonsignificant prostate cancer, which may lead to u...
Preliminary results from phase II enfortumab vedotin plus toripalimab compared to gemcitabine-cisplatin as neoadjuvant therapy for patients with muscle-invasive bladder cancer (MIBC).
782 Background: Cisplatin-based neoadjuvant chemotherapy is the standard of care in MIBC with improved overall survival (O...
Diagnostic performance of <sup>18</sup> F-flotufolastat PET/CT compared with conventional imaging in men with biochemical recurrence of prostate cancer: Descriptive post-hoc analysis from the phase 3 SPOTLIGHT study.
30 Background: SPOTLIGHT (NCT04186845) assessed the diagnostic performance of prostate-specific membrane antigen (PSMA)-ta...
Relevance of fresh frozen sections (FFS) for carcinoma in situ (CIS) detection in radical cystectomy for bladder cancer.
667 Background: Radical cystectomy is the standard of care for muscle invasive bladder cancer after neoadjuvant chemothera...
Oncological outcomes and HER2 expression of urothelial carcinoma with squamous differentiation: A retrospective study.
702 Background: Urothelial carcinomas (UCs) often exhibit regions of divergent differentiation, such as squamous different...
A dyadic exercise approach to prevent declines in physical and mental health in couples during radiation treatment for cancer: Protocol for a hybrid type I efficacy implementation trial.
TPS410 Background: Compared to couples that aren’t facing a chronic illness, both cancer patients and their spouses suffer...
Clinical utility of a urinary DNA methylation biomarker test in the diagnosis and surveillance of upper tract urothelial carcinoma: Results from a prospective trial.
822 Background: DNA methylation, an epigenetic modification frequently altered during tumorigenesis, has emerged as a prom...
An intra-patient contemporaneous comparison of <sup>18</sup> F-piflufolastat and <sup>18</sup> F-flotufolastat urinary radioactivity and local and pelvic region detection rates in men with low prostate-specific antigen biochemical recurrence of prostate cancer after radical prostatectomy.
32 Background: PET-based radiopharmaceuticals targeting prostate-specific membrane antigen (PSMA) have become the mainstay...